Published on Cpnhelp.org - Chlamydia Pneumoniae Treatment (http://www.cpnhelp.org)

Home > forums > Cpnhelp Discussion Forum > Cpn-related research: Member-posted > content

Coronary artery disease patient's first degree relatives (with Cpn) at higher risk for atherosclerosis.
By Jim K
Created 06/28/2008 - 11:17pm

  • Cpn-related research: Member-posted
Int J Cardiol. [1] 2008 Jun 20. [2]

Coronary artery disease patient's first degree relatives may be at higher risk for atherosclerosis.

Jha HC [3], Mittal A [4].

Division of Microbiology/Tissue Culture, Institute of Pathology (ICMR), Safdarjung Hospital Campus, Post Box no. 4909, New Delhi-110 029, India.

Our aim was to investigate the relationship between the serologic status concerning Chlamydia pneumoniae (Cp), Helicobacter pylori (Hp), Cytomegalovirus (CMV) and high sensitive C-reactive protein (hsCRP) in coronary artery disease (CAD) patient's first degree relatives, which remain an unrevealed issue in literature. We studied 192 CAD patients (pts), 140 CAD-patient first degree relatives (CAD-R) and 192 controls with no evidence of obstructive CAD. Seropositivity for Cp IgGi [5] (71 vs 50, p=0.090), Hp IgA (98 vs 59, p=0.06), Hp IgG (77 vs 55, p=0.09), CMV IgG (62 vs 44, p=1.00), Ct IgG (7 vs 6, p=0.78) was not significantly higher in CAD-pts compared to CAD-R. However, seropositivity to Cp IgA (154 vs 96, p=0.020) and hsCRP (114 vs 65, p=0.014) were significantly higher in CAD-pts compared to CAD-R. Further differences between CAD-R and controls were significant for all seropositive groups and hsCRP. Therefore, this study adds to the strong evidence of association of Cp specific IgA and hsCRP with CAD and CAD-R is at higher risk for disease progression.

___________________________________________________________

 

CAPi [6]i [6] for Cpni [7]i [7] 11/04. Dx: 25yrs CFSi [8]i [8] & FMSi [9]i [9]. Currently: 150mg BID Roxithromycin, Doxycycline 100mg BID, Tinii [10]i [10] 1000mg/day pulses; Vit D2000 units, T4 & T3

www.cpnhelp.org: devoted to the understanding and treatment of Chlamydia Pneumoniae in a variety of human diseases through combination antibiotic protocols.

Source URL (retrieved on 12/01/2008 - 4:47pm): http://www.cpnhelp.org/node/4701

Links:
[1] http://www.cpnhelp.org/javascript%3AAL_get%28this%2C+%27jour%27%2C+%27Int+J+Cardiol.%27%29%3B
[2] http://www.cpnhelp.org/javascript%3APopUpMenu2_Set%28Menu18572262%29%3B
[3] http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term="Jha HC"[Author]&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus
[4] http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term="Mittal A"[Author]&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus
[5] http://www.cpnhelp.org/taxonomy/term/53
[6] http://www.cpnhelp.org/glossary/term/168
[7] http://www.cpnhelp.org/glossary/term/167
[8] http://www.cpnhelp.org/glossary/term/163
[9] http://www.cpnhelp.org/taxonomy/term/24
[10] http://www.cpnhelp.org/chlamydia_pneumoniae/an_0